InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by McGrath Yvonne, Vice-Présidente, Recherche et Développement et Directrice Scientifique. Director active across 2 companies, notably iTeos Therapeutics, Inc.. In total, 11 filings have been logged. The latest transaction was filed on 1 March 2022 — Levée d'options. Regulator: SEC (Form 4). All data is free.
Declarations11 total
€37,80310,000 shares@ €3.780313.4% of flow
Common Stock
SEC:0001209191-22-015080:0·
€27,5467,927 shares@ €3.474925.3% of flow
Common Stock
SEC:0000899243-21-023000·
€27,5467,927 shares@ €3.47499.7% of flow
Common Stock
SEC:0000899243-21-023000:0·
€26,3267,604 shares@ €3.462224.2% of flow
Common Stock
SEC:0000899243-21-021777·
€27,4527,927 shares@ €3.463125.2% of flow
Common Stock
SEC:0000899243-21-021779·
€26,3267,604 shares@ €3.46229.3% of flow
Common Stock
SEC:0000899243-21-021777:0·
€27,4527,927 shares@ €3.46319.7% of flow
Common Stock
SEC:0000899243-21-021779:0·
€27,4527,927 shares@ €3.463125.2% of flow
Common Stock
SEC:0000899243-21-020733·
€27,4527,927 shares@ €3.46319.7% of flow
Common Stock
SEC:0000899243-21-020733:0·
€27,5797,926 shares@ €3.4795100.0% of flow
Common Stock
SEC:0000899243-21-019921·
€27,5797,926 shares@ €3.47959.7% of flow
Common Stock
SEC:0000899243-21-019921:0·
11 of 11 declarations
About McGrath Yvonne
Yvonne McGrath is VP, Research and Development and Chief Scientific Officer at iTeos Therapeutics, Inc. In this role, she oversees the company's research and development initiatives, ensuring innovation and advancement of scientific projects. Her expertise is essential to support the organization's mission.
